Global Alliance for TB Drug Development
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Global Alliance for TB Drug Development sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Global Alliance for TB Drug Development: 13 sponsored US clinical trials, none currently recruiting.
Global Alliance for TB Drug Development sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tuberculosis, with 3 trials.
Top-decile sponsor footprint
Global Alliance for TB Drug Development ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
NCT05526911
Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
NCT04865536
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
NCT04493671
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
NCT04309656
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
NCT03758612
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
NCT03199313
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
NCT03199339
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02288481
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
NCT02216331
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
NCT01768273
Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)
NCT01830439
Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects
NCT01828827
A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
NCT03202693
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
How the Global Alliance for TB Drug Development early-phase archive is shaped
13 indexed studies, none listed as recruiting (0% open); 13 completed (100%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Tuberculosis (3 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Global Alliance for TB Drug Development: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Global Alliance for TB Drug Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Global Alliance for TB Drug Development page
13 registered trials is a research-attention snapshot, not an endorsement of Global Alliance for TB Drug Development or any single study.
- None of Global Alliance for TB Drug Development's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Tuberculosis is the condition Global Alliance for TB Drug Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tuberculosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Global Alliance for TB Drug Development pipeline card: 13 registered trials from official public datasets.Report a data error.